Method and formulations for modulating Lyn kinase activity and treating related disorders

Details for Australian Patent Application No. 2012227275 (hide)

Owner Melior Pharmaceuticals I, Inc.

Inventors Reaume, Andrew; Saporito, Michael S.

Agent FB Rice

Pub. Number AU-A-2012227275

Parent 2006283211

Filing date 21 September 2012

Wipo publication date 11 October 2012

International Classifications

A61K 31/495 - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

A61P 3/04 Drugs for disorders of the metabolism

Event Publications

11 October 2012 Application Open to Public Inspection

  Published as AU-A-2012227275

11 October 2012 Complete Application Filed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012227276-Global terminal management using 2factor authentication

2012227274-Structural pneumatic accumulator system